# Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.

> **NCT01985009** · NA · COMPLETED · sponsor: **Echosens** · enrollment: 450 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DEVICE:** FibroScan® examination.

## Key facts

- **NCT ID:** NCT01985009
- **Lead sponsor:** Echosens
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-01-17
- **Final completion:** 2017-01-17
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01985009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01985009, "Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01985009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*